Abstract 1451P
Background
Immune checkpoint blockade (ICB) has significantly impacted the treatment landscape in non-small cell lung cancer (NSCLC). However, this benefit is restricted to a subset of patients. While these results are encouraging, it is crucial to identify those patients who benefit the most from ICB and those who are refractory. Here we investigate the potential utility of longitudinal serum proteomic profiling to identify predictive biomarkers.
Methods
We included 40 metastatic NSCLC patients who received ICB treatment at Hospital del Mar, Barcelona between 2017-2021. Patients were categorized as long-term responders (LTR, n=20) if they had maintained radiologic response for more than 2 years or non-responders (NR, n=20) if they had disease progression at first radiological evaluation. Serum protein levels were assessed longitudinally (before treatment, previous cycle 2) using the Olink® Explore 384 Oncology panel.
Results
LTR had a greater proportion of high PD-L1 expression (p=0.01). Analysis of baseline serum samples showed an increase in LTR of proteins levels related to apoptosis and autophagy (CASP8, ATG4A), TCR signaling pathway (STAT5B, CRACR2A) and myeloid differentiation (ZBTB16, ARG1) (p<0.05 for all proteins). Higher levels of proteins related to immunosuppression and tumorigenesis (PDCD1, TGFBR2, KLK4, KLK6) prior to the second cycle of ICB were associated with poorer response to ICB, with non-responders exhibiting significantly higher levels (p<0.05 for all). Gene set enrichment analysis showed that LTR had an increase in myeloid cell differentiation process, while higher levels of immunoregulatory interactions between lymphoid and non-lymphoid cells were observed in NR (p<0.001 for all).
Conclusions
Our findings suggest that patients with high levels of proteins related to apoptosis, autophagy, TCR signaling, and myeloid differentiation at baseline may identify LTR to ICB. Our study underscores the potential use of baseline and longitudinal assessment of serum proteomics as valuable tools for patient selection who are suitable candidates for ICB. Further studies are needed to validate these findings and establish their potential clinical utility.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Bellosillo Paricio: Financial Interests, Personal, Research Grant: Thermo Fisher, Roche Diagnostics, Roche Pharma, AstraZeneca; Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Janssen, Novartis; Financial Interests, Personal, Speaker’s Bureau: Janssen, Merck-Serono, Novartis, Qiagen, Thermo Fisher, Pfizer, Bristol Myers Squibb. E. Arriola: Financial Interests, Personal, Advisory Board: Roche, Boehringer Ingelheim, Lilly; Financial Interests, Personal, Invited Speaker: Takeda, MSD, AstraZeneca, BMS, Thermo Fisher Scientific, Guardant Health, Pfizer; Financial Interests, Personal, Other, Co-founder: Trialing Health; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20